32 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22618 | metastatic, RECIST 1.1 | Yassine Lalami | Oral cavity and lips | EORTC | 1206 - HNCG | Trial closed for recruitment | A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) | yassine.lalami@hubruxelles.be | 2 | 2 | |
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22684 | No prior gene therapy | Dirk Van Gestel | Head and Neck | Oragenics | AG013-ODOM-201 | Trial closed | A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22681 | *NTSR1 expression *Measureable disease RECIST 1.1 |
Patrick Flamen | Germ cell tumors | Ipsen | D-FR-01087-001 | Trial closed | An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors | patrick.flamen@hubruxelles.be | 1/2 | 1 | |
| 22768 | At least one measurable lesion | Yassine Lalami | Bones - soft tissue | AstraZeneca | D5660C00004 | Trial closed | A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | yassine.lalami@hubruxelles.be | 1/2 | 1 | |
| 22699 | T1 or T2 N0,M0 | Esther Willemse | Head and Neck | EORTC | EORTC 1420-HNCG-ROG | Trial open for recruitment | Phase III study assessing the ?best of? radiotherapy compared to the ?best of? surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma | esther.willemse@hubruxelles.be | 3 | 3 | |
| 28559 | Tatiana Dragan | EORTC | EORTC 1629 | Trial open for recruitment | Late toxicity and long-term quality of life in head and neck cancer survivors | accueil.cons.radiotherapie@hubruxelles.be | |||||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention |